Dr. Chandra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St
Chicago, IL 60611Phone+1 312-695-5378Fax+1 312-695-0188
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2008 - 2011
Michigan State University College of Human MedicineClass of 2008
Certifications & Licensure
IL State Medical License 2014 - 2026
NY State Medical License 2011 - 2016
OH State Medical License 2008 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Start of enrollment: 2019 May 17
- Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Jul 08
Publications & Presentations
PubMed
- Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24 - A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
Journal of the American Academy of Dermatology. 2025-01-01 - Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.Sylvia Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina
Clinical Cancer Research. 2024-12-30
Press Mentions
Scientists Discover Potential Biomarker in Rare Skin CancerJuly 26th, 2024- The Importance of Having Difficult Conversations with PatientsDecember 2nd, 2022
- mRNA Vaccines Get Ready for Their Next Act: Fighting CancerSeptember 21st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
